BSE filing, NSE: AMARDEE. Summary written from the filing by ALFA Finder's alert engine.
Amerise Biosciences Ltd: key numbers
- Share price
- ₹0.84
- Market cap
- ₹5.55 Cr
- Revenue (annual)
- ₹0.00 Cr
- Net profit (annual)
- ₹0.02 Cr
- P/E (TTM)
- -105.1×Sector 26.2×
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Amerise Biosciences Ltd
All →Amerise Biosciences Board Meeting Date
Amerise Biosciences will hold a board meeting on 30 October 2026 to consider Q2 and H1 FY27 unaudited results. This is an advance notice of a future meeting with no financial figures disclosed.
Amerise Biosciences Other Announcement
Amerise Biosciences Ltd filed its quarterly shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI regulatory requirements.
Amerise Biosciences Annual General Meeting
Amerise Biosciences Limited conducted its 41st Annual General Meeting on September 24, 2026. Shareholders approved financial statements and the appointment of a new Wholetime Director and CFO.
Amerise Biosciences Annual Report
Amerise Biosciences has submitted its Annual Report for the financial year 2024-25. The company scheduled its 41st Annual General Meeting for September 24, 2026.
Amerise Biosciences Annual General Meeting
Amerise Biosciences Ltd has submitted the notice for its 41st Annual General Meeting, scheduled to be held on September 24, 2026.
Amerise Biosciences Management Change
Amerise Biosciences Limited has appointed Ms. Soni Pandiya as the new Company Secretary, replacing Ms. Minal Lakhani who resigned for better career opportunities.
Other capital structure change announcements
All →Apar Industries Capital Structure Change
APAR Industries will infuse up to USD 100 million in cash into wholly owned subsidiary PSPL during FY2026-27. The infusion is valued at Rs.952.40 Crore.
- Value
- ₹952.4 Cr
- Execution
- FY 2026-27, in single or multiple tranches
Advanced Enzyme Technologies Capital Structure Change
Advanced Enzyme Technologies bought back 54,455 equity shares via Emkay Global on October 29, 2026 at an average of ₹263.76. Cumulative buyback stands at 24,10,906 shares under the ongoing open-market programme.
- Value
- ₹1.44 Cr
63 Moons Technologies Capital Structure Change
63SATS, a subsidiary of 63 Moons, signed a warrant subscription deal with BCCL. BCCL pays Rs 6.5 Crore upfront, deferring dilution until warrant exercise.
- Value
- ₹6.50 Cr
63 Moons Technologies Capital Structure Change
Material subsidiary 63SATS Cybertech signed a warrant subscription agreement with Bennett Coleman for 65 warrants. Aggregate warrant value is Rs.65 Crore, with 10% (Rs.6.5 Crore) payable upfront.
- Value
- ₹65.00 Cr
Otco International Capital Structure Change
OTCO International Ltd fixed 06 November 2026 as the record date for consolidating 5 equity shares of Rs.2 face value into 1 share of Rs.10 face value. The consolidation was approved by shareholders at the AGM held 17 September 2026.
Meesho Capital Structure Change
Meesho will invest up to USD 1 lakh in cash, in tranches, in its wholly owned US subsidiary. Its 100% holding stays unchanged, worth about ₹0.01 Crore.
- Value
- ₹0.01 Cr